Annals of Oncology

In this issue:

Contents of the next issue
Ann Oncol 4: 615.
[PDF] [Request Permissions]

News:

U.S. Congress upholds ban on HIV carriers
Ann Oncol 4: 616.
[PDF] [Request Permissions]

New policy alarms French cancer centers
Ann Oncol 4: 616.
[PDF] [Request Permissions]

The Italian National Oncology Committee survives government changes
Ann Oncol 4: 616.
[PDF] [Request Permissions]

Germany plans to restructure medical research
Ann Oncol 4: 617.
[PDF] [Request Permissions]

Kleihues elected director of IARC
Ann Oncol 4: 617-618.
[PDF] [Request Permissions]

The Swiss Parliament: No ban on tobacco and alcohol advertisement
Ann Oncol 4: 618.
[PDF] [Request Permissions]

Perhaps not everyone knows that...
Ann Oncol 4: 618-620.
[PDF] [Request Permissions]

Editorial:

A. M. Levine, M.D.

Hodgkin's disease in the setting of HIV infection
Ann Oncol 4: 621-622.
[PDF] [Request Permissions]

Book reviews:

Martin F. Fey

Book Review
Ann Oncol 4: 622.
[PDF] [Request Permissions]

A. Gallino

Book review
Ann Oncol 4: 633.
[PDF] [Request Permissions]

Ennio Pedrinis

Book Review
Ann Oncol 4: 699.
[PDF] [Request Permissions]

G. Domenighetti

Book Review
Ann Oncol 4: 702.
[PDF] [Request Permissions]

Review:

R. Brown

p53: A target for new anticancer drugs or a target for old drugs?
Ann Oncol 4: 623-629.
[PDF] [Request Permissions]

Commentary:

T. Barbui

Leukemia... the next questions: International Conference held in Houston, TX, March 24–27, 1993
Ann Oncol 4: 631-633.
[PDF] [Request Permissions]

Original articles:

J. M. Andrieu, S. Roithmann, J. M. Tourani, R. Levy, B. Desablens, C. le Maignan, J. A. Gastaut, P. Brice, M. Raphael, and B. Taillan

Hodgkin's disease during HIV1 infection: The French Registry Experience
Ann Oncol 4: 635-641.
[Abstract] [PDF] [Request Permissions]

M. F. X. Gnant, G. H. Blijham, A. Reiner, M. Schemper, M. Reynders, B. Schutte, C. van Asche, G. Steger, and R. Jakesz

Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer — 10-year results
Ann Oncol 4: 643-650.
[Abstract] [PDF] [Request Permissions]

E. Lepage, C. Gisselbrecht, C. Haioun, C. Sebban, H. Tilly, A. Bosly, P. Morel, R. Herbrecht, F. Reyes, and B. Coiffier

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol
Ann Oncol 4: 651-656.
[Abstract] [PDF] [Request Permissions]

L. Salvagno, M. Sorarù, S. M. L Aversa, A. Bianco, V. Chiarion Sileni, G. L. Pappagallo, and M. V. Fiorentino

Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy
Ann Oncol 4: 657-662.
[Abstract] [PDF] [Request Permissions]

S. A. Tjulandin, A. M. Garin, A. A. Mescheryakov, N. I Perevodchikova, V. A. Gorbunova, A. V. Sokolov, N. V. Ljubimova, G. T. Mironova, G. V. Molchanov, R. F. Ozols, and J. M. Hamilton

Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumor
Ann Oncol 4: 663-667.
[Abstract] [PDF] [Request Permissions]

S. Frustaci, S. Foladore, A. Buonadonna, A. De Paoli, D. Crivellari, A. Carbone, R. Sorio, S. Morassut, and S. Monfardini

Epirubicin and ifosfamide in advanced soft tissue sarcomas
Ann Oncol 4: 669-672.
[Abstract] [PDF] [Request Permissions]

J. Verweij, B. Lund, J. Beijnen, M. de Boer-Dennert, I. Koier, H. Rosing, and H. Hansen

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
Ann Oncol 4: 673-678.
[Abstract] [PDF] [Request Permissions]

V. Ribrag, J.-P. Droz, J. Morizet, B. Leclercq, A. Gouyette, and G. G. Chabot

Test dose-guided administration of cisplatin in an anephric patient: A case report
Ann Oncol 4: 679-682.
[Abstract] [PDF] [Request Permissions]

Clinical Case:

G. Daugaard

Tamoxifen and hypercalcaemia
Ann Oncol 4: 683-687.
[PDF] [Request Permissions]

Short reports:

M. Lopez, S Carpano, A. Cancrini, M. Marcellini, P. Del Medico, M. Rinaldi, P. Vici, G. Paoletti, and L. Di Lauro

Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma
Ann Oncol 4: 689-691.
[Abstract] [PDF] [Request Permissions]

R. W. C. Gregg, L. Kaizer, S. Fine, K. Gelmon, G. Wielgosz, and E. Eisenhauer

A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer
Ann Oncol 4: 693-694.
[PDF] [Request Permissions]

T. Shore, E. Eisenhauer, I. Quirt, K. Belanger, R. Lohmann, H. Silver, and G. Wielgosz

A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: A study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG)
Ann Oncol 4: 695-696.
[PDF] [Request Permissions]

C. Dittrich, M. Baur, N. Vavra, M. Hudec, B. Fazeny, M. Barrada, H. Salzer, and P. Sevelda

Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients
Ann Oncol 4: 697-699.
[Abstract] [PDF] [Request Permissions]

Letter to the editor:

F. Roila, L. Crinò, G. Carloni, and G. Natalini

Cyproterone acetate: hepatoxicity and prostatic cancer treatment
Ann Oncol 4: 701.
[PDF] [Request Permissions]

G. Domenighetti

Approved drugs for unlabeled uses: National health cost containment denies access to state-of-the-art cancer therapies in Italy
Ann Oncol 4: 701-702.
[PDF] [Request Permissions]

Corrigendum:

Corrigendum
Ann Oncol 4: 703.
[Abstract] [PDF] [Request Permissions]

Advertisements in this issue:

Classified advertisements from ESMO members and meeting announcements
Ann Oncol 4: 704.
[PDF] [Request Permissions]

Sandoz Pharma Ltd and Schering-Plough International
Ann Oncol 4: 705.
[PDF] [Request Permissions]

Kluwer Academic Publishers
Ann Oncol 4: 706-707.
[PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.